Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | ZW25 |
| Synonyms | |
| Therapy Description |
Zanidatamab (ZW25) is a bispecific antibody targeting ERBB2 (HER2), which induces anti-tumor immune response against Erbb2 (Her2)-expressing tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P, PMID: 32054397). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZW25 | ZW-25|Zanidatamab | HER2 (ERBB2) Antibody 72 | Zanidatamab (ZW25) is a bispecific antibody targeting ERBB2 (HER2), which induces anti-tumor immune response against Erbb2 (Her2)-expressing tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P, PMID: 32054397). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04466891 | Phase II | ZW25 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | 3 |
| NCT05615818 | Phase III | Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib | Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) | Not yet recruiting | GBR | FRA | BEL | 0 |
| NCT04578444 | Expanded access | ZW25 | An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer | Available | USA | ITA | GBR | FRA | ESP | 0 |
| NCT04513665 | Phase II | ZW25 | ZW25 in Women With Endometrial Cancers | Completed | USA | 0 |
| NCT05035836 | Phase II | Letrozole + ZW25 ZW25 Tamoxifen + ZW25 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | Active, not recruiting | USA | 0 |
| NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Active, not recruiting | USA | CAN | 1 |
CKB BOOST